Nektar Therapeutics Investment Income, Interest
Nektar Therapeutics (NKTR) reported Investment Income, Interest of $9.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-14
- Nektar Therapeutics investment income, interest for the quarter ending 2026-06-30 was $9.35M, a 374.66% increase year-over-year.
- Nektar Therapeutics investment income, interest for the quarter ending 2026-03-31 was $4.24M, a 47.60% increase year-over-year.
- Nektar Therapeutics investment income, interest for the quarter ending 2025-12-31 was $2.78M, a 5.64% decline year-over-year.
- Nektar Therapeutics investment income, interest for the quarter ending 2025-09-30 was $2.82M, a 17.98% decline year-over-year.
- Nektar Therapeutics investment income, interest for fiscal 2025 was $10.44M, a 28.01% decline from fiscal 2024.
- Nektar Therapeutics investment income, interest for fiscal 2024 was $14.50M, a 23.72% decline from fiscal 2023.
- Nektar Therapeutics investment income, interest for fiscal 2023 was $19.01M, a 180.24% increase from fiscal 2022.
- Nektar Therapeutics investment income, interest for fiscal 2022 was $6.78M, a 148.37% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.35M 10-Q · filed 2026-08-14 | $13.59M 10-Q · filed 2026-08-14 | $16.36M derived: sum of 3 quarters · filed 2026-08-14 | $19.18M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.24M 10-Q · filed 2026-05-08 | $7.02M derived: sum of 2 quarters · filed 2026-05-08 | $9.84M derived: sum of 3 quarters · filed 2026-05-08 | $11.81M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $5.59M derived: sum of 2 quarters · filed 2026-03-13 | $7.56M derived: sum of 3 quarters · filed 2026-08-14 | $10.44M 10-K · filed 2026-03-13 |
| 2025-09-30 | $2.82M 10-Q · filed 2025-11-07 | $4.79M derived: sum of 2 quarters · filed 2026-08-14 | $7.66M 10-Q · filed 2025-11-07 | $10.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.97M 10-Q · filed 2026-08-14 | $4.84M 10-Q · filed 2026-08-14 | $7.79M derived: sum of 3 quarters · filed 2026-08-14 | $11.22M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.87M 10-Q · filed 2026-05-08 | $5.82M derived: sum of 2 quarters · filed 2026-05-08 | $9.25M derived: sum of 3 quarters · filed 2026-05-08 | $13.15M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $6.38M derived: sum of 2 quarters · filed 2026-03-13 | $10.28M derived: sum of 3 quarters · filed 2026-03-13 | $14.50M 10-K · filed 2026-03-13 |
| 2024-09-30 | $3.44M 10-Q · filed 2025-11-07 | $7.34M derived: sum of 2 quarters · filed 2025-11-07 | $11.56M 10-Q · filed 2025-11-07 | $16.18M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $3.90M 10-Q · filed 2025-08-08 | $8.12M 10-Q · filed 2025-08-08 | $12.74M derived: sum of 3 quarters · filed 2025-08-08 | $17.95M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $4.22M 10-Q · filed 2025-05-09 | $8.84M derived: sum of 2 quarters · filed 2025-05-09 | $14.05M derived: sum of 3 quarters · filed 2025-05-09 | $18.89M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $9.83M derived: sum of 2 quarters · filed 2025-03-14 | $14.67M derived: sum of 3 quarters · filed 2025-03-14 | $19.01M 10-K · filed 2025-03-14 |
| 2023-09-30 | $5.21M 10-Q · filed 2024-11-08 | $10.06M derived: sum of 2 quarters · filed 2024-11-08 | $14.39M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $4.85M 10-Q · filed 2024-08-09 | $9.18M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $4.33M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $6.78M 10-K · filed 2024-03-05 | |||
| 2021-12-31 | $2.73M 10-K · filed 2024-03-05 | |||
| 2014-09-30 | $133.00K 10-Q · filed 2014-11-07 | $265.00K derived: sum of 2 quarters · filed 2014-11-07 | $399.00K 10-Q · filed 2014-11-07 | $492.00K derived: sum of 4 quarters · filed 2014-11-07 |
| 2014-06-30 | $132.00K 10-Q · filed 2014-08-01 | $266.00K 10-Q · filed 2014-08-01 | $359.00K derived: sum of 3 quarters · filed 2014-08-01 | $475.00K derived: sum of 4 quarters · filed 2014-11-07 |
| 2014-03-31 | $134.00K 10-Q · filed 2014-05-08 | $227.00K derived: sum of 2 quarters · filed 2014-05-08 | $343.00K derived: sum of 3 quarters · filed 2014-11-07 | $552.00K derived: sum of 4 quarters · filed 2014-11-07 |
| 2013-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $209.00K derived: sum of 2 quarters · filed 2014-11-07 | $418.00K derived: sum of 3 quarters · filed 2014-11-07 | $732.00K 10-K · filed 2014-02-27 |
| 2013-09-30 | $116.00K 10-Q · filed 2014-11-07 | $325.00K derived: sum of 2 quarters · filed 2014-11-07 | $639.00K 10-Q · filed 2014-11-07 | $1.09M derived: sum of 4 quarters · filed 2014-11-07 |
| 2013-06-30 | $209.00K 10-Q · filed 2014-08-01 | $523.00K 10-Q · filed 2014-08-01 | $973.00K derived: sum of 3 quarters · filed 2014-08-01 | $1.58M derived: sum of 4 quarters · filed 2014-08-01 |
| 2013-03-31 | $314.00K 10-Q · filed 2014-05-08 | $764.00K derived: sum of 2 quarters · filed 2014-05-08 | $1.37M derived: sum of 3 quarters · filed 2014-05-08 | $2.00M derived: sum of 4 quarters · filed 2014-05-08 |
| 2012-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $1.05M derived: sum of 2 quarters · filed 2014-02-27 | $1.68M derived: sum of 3 quarters · filed 2014-02-27 | $2.31M 10-K · filed 2014-02-27 |
| 2012-09-30 | $603.00K 10-Q · filed 2013-11-07 | $1.23M derived: sum of 2 quarters · filed 2013-11-07 | $1.86M 10-Q · filed 2013-11-07 | $2.53M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $630.00K 10-Q · filed 2013-08-09 | $1.26M 10-Q · filed 2013-08-09 | $1.92M derived: sum of 3 quarters · filed 2014-02-27 | $2.54M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $632.00K 10-Q · filed 2013-05-09 | $1.29M derived: sum of 2 quarters · filed 2014-02-27 | $1.92M derived: sum of 3 quarters · filed 2014-02-27 | $2.44M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $661.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $1.28M derived: sum of 2 quarters · filed 2014-02-27 | $1.81M derived: sum of 3 quarters · filed 2014-02-27 | $2.24M 10-K · filed 2014-02-27 |
| 2011-09-30 | $622.00K 10-Q · filed 2012-11-09 | $1.15M derived: sum of 2 quarters · filed 2012-11-09 | $1.58M 10-Q · filed 2012-11-09 | $1.90M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $529.00K 10-Q · filed 2012-08-09 | $961.00K 10-Q · filed 2012-08-09 | $1.28M derived: sum of 3 quarters · filed 2013-03-01 | $1.65M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $432.00K 10-Q · filed 2012-05-04 | $752.00K derived: sum of 2 quarters · filed 2013-03-01 | $1.12M derived: sum of 3 quarters · filed 2013-03-01 | $1.51M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $689.00K derived: sum of 2 quarters · filed 2013-03-01 | $1.08M derived: sum of 3 quarters · filed 2013-03-01 | $1.54M 10-K · filed 2013-03-01 |
| 2010-09-30 | $369.00K 10-Q · filed 2011-11-04 | $762.00K derived: sum of 2 quarters · filed 2011-11-04 | $1.23M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $393.00K 10-Q · filed 2011-08-05 | $856.00K 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $463.00K 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | $3.69M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |